---
title: "PMV Pharmaceuticals Enters Underwriting Agreement With TD Securities for ~$47 Million Offering"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297766378.md"
description: "PMV Pharmaceuticals signed an underwriting agreement with TD Securities for a $47 million offering of common stock and warrants, closing on Sep 02, 2026. The deal includes 22.05M shares and associated warrants at $1.21 per unit. Proceeds will fund late-stage development and commercialization prep for rezatapopt."
datetime: "2026-09-02T10:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297766378.md)
  - [en](https://longbridge.com/en/news/297766378.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297766378.md)
generator: "portal-rs"
---

# PMV Pharmaceuticals Enters Underwriting Agreement With TD Securities for ~$47 Million Offering

PMV Pharmaceuticals entered into an Underwriting Agreement with TD Securities to conduct an underwritten offering of common stock, pre-funded warrants, and accompanying common stock warrants, expected to close on Sep 02, 2026. The deal includes 22,055,000 shares, 19,900,000 pre-funded warrants, and 41,955,000 accompanying warrants at a combined price of $1.21 per share-unit, generating estimated net proceeds of approximately $47.0 million. Warrants are immediately exercisable, with common stock warrants expiring five years from issuance and featuring reset and potential mandatory exercise provisions tied to FDA NDA acceptance milestones. Proceeds will support late-stage development, regulatory submission, and commercialization preparation for rezatapopt.

**Agreement details:**

-   **Agreement type**: Underwriting agreement for underwritten equity and warrant offering
-   **Counterparty**: TD Securities
-   **Signed / Effective**: Aug 31 2026 / same
-   **Duration / Termination**: At will
-   **Reason**: Fund late-stage rezatapopt development and commercialization prep

Original SEC Filing: PMV Pharmaceuticals, Inc. \[ PMVP \] - 8-K - Sep. 01, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [PMVP.US](https://longbridge.com/en/quote/PMVP.US.md)
- [TD.US](https://longbridge.com/en/quote/TD.US.md)

## Related News & Research

- [BUZZ-Oncology firm PMV Pharma falls on $51 mln stock-and-warrants sale](https://longbridge.com/en/news/297642898.md)
- [PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push](https://longbridge.com/en/news/297657742.md)
- [Bank of America Q3 Preview: Stock Down in 2026, Could 5th Straight Double Beat Change Momentum?](https://longbridge.com/en/news/301739892.md)
- ["The Market Gets It Wrong," Says Investor About CoreWeave Stock](https://longbridge.com/en/news/301869526.md)
- [CoreWeave Chief Revenue Officer Jonathan Jones Reports Disposal of $2.94 Million in Common Shares](https://longbridge.com/en/news/301896236.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**